Google快讯 - lung cancer

	lung cancer 实时更新 ⋅ 2023年5月31日
	新闻
	Bristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review | Nasdaq Nasdaq Bristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review. May 31, 2023 — 12:09 pm EDT. Written by Zacks Equity Research for Zacks ->. 标记为不相关
	Acclaim-1 Trial of Quaratusugene Ozeplasmid Plus Osimertinib in NSCLC Advances Into ... - OncLive OncLive ... ozeplasmid in combination with osimertinib in patients with advanced non–small cell lung cancer can proceed to the phase 2 expansion portion. 标记为不相关
	The value of HPV self-sampling kits - Contemporary OB/GYN Contemporary OB/GYN In a recent study, women taking higher cumulative dosages of hormone therapy had a reduced risk of developing lung cancer. Read More. 标记为不相关
查看更多结果 | 修改此快讯

您收到此电子邮件是因为您订阅了Google快讯。 退订 | 查看您所有的快讯

以RSS Feed的形式接收此快讯

发送反馈